High Myopia, Macular Schisis
Conditions
Keywords
Posterior scleral reinforcement, Macular ischemia
Brief summary
The purpose of this study is to assess the primary safety and efficacy of High Myopic Posterior Scleral Fixation System in the treatment of macular schisis caused by high myopia.
Detailed description
Posterior Scleral Reinforcement（PSR） is the only surgical method that can delay the the development of high myopia. However, The surgical method is restricted by the material source limitation and macular ischemia in the eye after reinforcement. The investigators have designed a new posterior scleral fixation system，Its basic material is medical silicone，The product is designed to solve the problem of material source limitation and macular ischemia in the eye after reinforcement.
Interventions
DEVICEHigh Myopic Posterior Scleral Fixation System
Implant HM into the eye through posterior scleral reinforcement
Sponsors
GuangZhou WeiShiBo Biotechnology Co., ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18\ 65, male or female; 2. Refractive ranges from -6.00d to -25.00d; 3. The axial length of the operative eye was 26-32mm; 4. Macular cleavage 200-1000μm; 5. Corrected visual acuity of the operative eye \< 0.3; 6. Able to understand the purpose of the test, voluntarily participate and sign the informed consent form.
Exclusion criteria
1. Known allergy to silica gel and patients with scar constitution; 2. Ocular inflammation; 3. Fundus hemorrhage; 4. Macular hole; 5. Macular cleavage of the contralateral eye greater than 200μm; 6. Corrected visual acuity of contralateral eye \< 0.4; 7. Opacity of the refractive medium; 8. Eye tumor; 9. History of hyperthyroidism; 10. Other ophthalmic concomitant diseases that cannot be controlled, such as diabetic retinopathy, hypertensive fundus lesions, optic nerve atrophy, etc.; 11. Severe impairment of liver and kidney function and/or severe systemic diseases (such as cardiovascular, respiratory, digestive, nervous, endocrine, genitourinary, etc., depending on the tolerance of surgery); 12. Women who are pregnant (determined by a blood pregnancy test at the first visit), who are preparing for pregnancy during the test, and who are breastfeeding; 13. a history of drug abuse or alcohol abuse; 14. participate in other drug or medical device clinical trials within 30 days prior to the screening of this clinical trial; 15. Any condition of the subject that the study physician considers to be an impediment to the clinical trial (e.g. subject's susceptibility to mental stress, uncontrollable mood, depression, etc.); 16. Poor compliance of the subject, unable to complete the test process as required.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Macular reduction rate | 24 weeks | 24 weeks after implantation of the High Myopic Posterior Scleral Fixation System |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Best corrected visual acuity | Baseline (Before surgery), 1 day, 1 week, 4 weeks, 12 weeks, 24 weeks, | ETDRS table |
| Axial length | Baseline (Before surgery), 24 weeks after surgery | A-scan |
| Diopter | Baseline (Before surgery), 24 weeks after surgery | Refractometer |
Countries
China
Contacts
Primary ContactQianying Gao, MD,Ph.D
Outcome results
None listed